Annual General Meeting of Q-Med AB (publ)

Annual General Meeting of Q-Med AB (publ)

The Annual General Meeting of Q-Med AB (publ) was held on April 29, 2009 at 3
p.m. 

Dividend
The meeting adopted a resolution that no dividend is to be paid to the
shareholders.

Board and fees
The meeting adopted a resolution to re-elect the following members of the Board:
Bertil Hult, Ulf Mattsson, Anders Milton, Tomas Nicolin, Kristina Persson and
Bengt Ågerup for the period up until the end of the next Annual General Meeting.
The meeting also re-elected Anders Milton as the Chair of the Board.

The meeting also adopted a resolution that Board fees of 1,400,000 SEK in total
be paid for the period 2009/2010, in accordance with the proposal of the
Election Committee, with 450,000 SEK to the Chair of the Board, 250,000 SEK to
each of  Ulf Mattsson, Tomas Nicolin and Kristina Persson, and 200,000 SEK to
Bertil Hult. Bengt Ågerup is an employee of the company and shall therefore not
receive a Board fee.

Auditors' fees shall be paid in accordance with reasonable invoicing.

An unchanged fee of 200,000 SEK in total shall be paid for work on the audit
committee, with 100,000 SEK to the Chair of the committee and 50,000 SEK to each
of the other two committee members.

Election Committee
The meeting adopted a resolution that the election committee shall consist of
five members. Bengt Ågerup and Anders Milton, the Chair of the Board, were
elected as members, while Robert Wikholm was elected as Chair with the
assignment of finding, at the latest during the third quarter, two
representatives from the major institutional owners, to be included as members
of the election committee together with the three above-mentioned persons. No
fee is to be paid to the election committee.

Principles for remuneration
The meeting adopted a resolution on principles for remuneration and other
conditions of employment for senior management in accordance with the proposal
of the Board.

Change in the Articles of Association
A resolution was adopted that the first sentence of §8 of the Articles of
Association shall have the following wording and that a new second sentence be
added as follows: Notice of the General Meeting of the shareholders shall be
given through an announcement in the Swedish Official Gazette (Post och Inrikes
Tidningar) and on the company's website. It is to be published in Svenska
Dagbladet that notice has been given. The resolution is on the condition that
the change in the way of giving notice of the General Meeting of the
shareholders has come into force in the Swedish Companies Act (SFS 2005:551),
meaning that the proposed wording of §8 above is consistent with the Swedish
Companies Act.


Queries should be addressed to:
Carina Bolin, General Counsel
Tel: +46 70 974 9117
Kristin Ermanbriks, Manager Corporate Administration
Tel: +46 70 974 9071

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
just over 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of the NASDAQ OMX Nordic. 


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.